Amtagvi (lifileucel) is now available as SECOND line therapy for patients with unresectable or metastatic melanoma
Northside’s Immunotherapy Program is the ONLY approved TIL treatment center in Georgia.
Eligibility:
>18 years of age with unresectable or metastatic melanoma
Must have progressed on at least 1 previous systemic therapy, including a PD-L1 antibody, and if they had BRAF V600E mutation-positive disease, a BRAF or BRAF/MEK inhibitor
At least 1 resectable lesion
To schedule a patient consultation, please call The Blood & Marrow Transplant Group of Georgia at 404-255-1930.
2023 National Leaders in Allogeneic Transplantation
NH-BMT is the ONLY BMT program in the country and the only BMT program in Georgia to have achieved survival outcomes that significantly exceeded the expected survival rate for allogeneic and unrelated donor transplants for the last 15 consecutive reporting cycles (2009–2023) and is one of only 12 national centers (less than 10% of all centers) to over-perform for the current annual reporting cycle.
The program’s actual one-year survival rate, as reported in the Center for International Blood and Marrow Transplant Research (CIBMTR) final 2023 Transplant Center Specific Survival Report, is 81.9%.*
Specific transplant center information can be found at bethematch.org.*
Aleyah’s story: Overcoming stage 4 Hodgkin’s lymphoma
Aleyah Garnett of Atlanta was diagnosed with stage 4 Hodgkin’s Lymphoma in September 2017.
Over the next year, she endured several long rounds of high-dose chemotherapy under the care of her oncologist, Dr. Jayanthi Srinivasiah, known as Dr. Jay.
Addressing bone marrow health disparities
July is recognized as African American Bone Marrow Awareness Month, an opportunity to highlight health disparities affecting Black and African American patients in need of life-saving blood stem cell and bone marrow therapies.
We asked Dr. Lizamarie Bachier, an attending physician with the Northside’s blood and marrow transplant and hematologic malignancy programs, to discuss these disparities and what can be done to increase access to treatment options and improve outcomes.
From pain to hope: A sickle cell survivor's journey
Chelsea Uche, a 23-year-old sickle cell survivor, shares her inspiring journey from diagnosis to overcoming the challenges of living with this inherited blood disorder. Diagnosed with sickle cell shortly after birth, Chelsea describes how the disease affected her physically, emotionally and socially.
“Growing up with sickle cell, I had a very tough time with everything, truthfully. I was in the hospital consistently. I suffered with very bad chronic pain,” she said.
Q&A: CAR T-cell therapy
Dr. Melhem Solh, medical director of the cellular therapy program at Northside Hospital, answers common questions about CAR T-cell therapy and discusses its role in the treatment of cancer.
What is CAR T-cell therapy and how does it work?
Dr. Solh: CAR T-cell therapy, or chimeric antigen receptor T-cell therapy, is an advanced form of cancer treatment that uses the body’s own immune system to fight cancer cells. A patient’s own T-cells are engineered to find and destroy cancer cells. When the cells are infused back into the patient, they will attack the cancer and get rid of it.
Clinical trials help fight against cancer
We would like to highlight the importance and life-saving cancer research taking place at Northside’s BMT/Leukemia/Immunotherapy programs to improve treatment and quality of life for those fighting cancer.
Cancer clinical trials have resulted in new drugs and more effective treatments. Today, patients with cancer are living longer lives because of this shared research. Moreover, the conduct of research is expanding and providing enhanced access to those who may not have had such ease of access before.
The Blood and Marrow Transplant Program at Northside Hospital (NH-BMT) provides the best of both worlds—clinical excellence and compassionate care. We are committed to being the premier program in the Southeast, providing exceptional, state-of-the-art care to patients undergoing acute leukemia treatment, CAR T-cell immunotherapy, and blood and marrow stem cell transplantation. New patient brochure
